A Framework for Fitness-for-Purpose and Reuse in Computational Phenotyping
November 17, 2025
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Administer a dose of 9 mcg/kg once a day by IV infusion given over 30 to 60 minutes for five days up to every 21 days course in eight cycles
Indicated for Chronic or Small Lymphocytic Lymphoma:
Follow a weekly progress schedule over a period of 5 weeks to gradually enhance the dose to the recommended daily dose intake of 400 mg.
progress dosing schedule is generally designed to gradually decrease tumor burden and diminish risk of tumor lysis syndrome.
Week 1-20 mg orally one time a day.
Week 2-50 mg orally one time a day.
Week 3-100 mg orally one time a day.
Week 4-200 mg orally one time a day.
Week 5 and after-400 mg orally one time a day.
Monotherapy
400 mg orally every day after completing the 5-week dosage schedule.
Continue treatment until there is evidence of disease progression or the occurrence of unacceptable toxicity.
Combination with Obinutuzumab
1-cycle
Day 1- Obinutuzumab 100 mg intravenously
Day 2- Obinutuzumab 900 mg intravenously
Days 8 & 15- Obinutuzumab 1000 mg intravenously
Day 22- Start venetoclax dosing according to the 5-week ramp-up schedule.
2-cycle
Day 1- Obinutuzumab 100 mg intravenously.
Day 28-After completion of the ramp-up schedule on 2-cycle day 28, continue the venetoclax dosing 400 mg every day from 3-cycle day-1 to 12-cycle day-28.
3-6 cycle
Day 1- Obinutuzumab 100 mg intravenously.
Day 1 to 28-Continue venetoclax 400 mg orally every day.
7-12 cycle
Day 1 to 28-Continue venetoclax 400 mg orally every day.
Combination with rituximab
Venetoclax
Complete the 5-week ramp-up dosing schedule to reach 400 mg orally every day.
Continue the venetoclax dosing 400 mg orally every day for 24 months from the 1-cycle day-1 of rituximab.
Rituximab
Initiate 375 mg/m² Intravenously after the patient has received venetoclax 400 mg every day for 7 days.
500 mg/m² Intravenously on day-1 for 2-6 cycles.
Acute Myeloid Leukemia
venetoclax dosing generally depends on a combination agent.
Day 1-100 mg orally every day.
Day 2-200 mg orally every day.
Day 3-400 mg orally every day.
Day 4 and after (combination with azacitidine /decitabine): 400 mg orally every day.
Day 4 and after (combination with low dosage cytarabine): 600 mg orally every day.
combination with azacitidine, decitabine or low-dose cytarabine- Continue treatment until there is evidence of disease progression or the occurrence of unacceptable toxicity.
Administering a dosage of 800 mg orally daily
For adult weight 70 kg: The recommended dose is 74-185 MBq, which is equivalent to 2-5 MCi
The injection is for IV administration
Canine Lymphorma (off-label)
It's recommended for treating canine lymphoma
Provide the dog with a meal just before administering this medication
Use protective disposable chemotherapy-resistant gloves while handling this drug
Initiate the administration of medication at an initial dosage of 1.25 mg per kg orally twice a week (for example, on Monday and Thursday or Tuesday and Friday), ensuring a minimum of 72 hours :
Dose Adjustments
Limited data is available
Canine Lymphorma (off-label)
It's recommended for treating canine lymphoma
Provide the dog with a meal just before administering this medication
Use protective disposable chemotherapy-resistant gloves while handling this drug
Initiate the administration of medication at an initial dosage of 1.25 mg per kg orally twice a week (for example, on Monday and Thursday or Tuesday and Friday), ensuring a minimum of 72 hours :
Future Trends
References

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
